Immunity Against Carcinogenesis

Strategic Inhibition of Cancer Initiation & Propagation

Dr. Karriem H. Ali, MD Chief Scientific Officer Pharmacognosia

A current understanding of the interactions between malignant species and specific cells of the immune system is here presented, with a specific focus on the actions of the innate immune system against pre-malignant and malignant cells. From this perspective, our current research findings are considered, providing a basis for novel preventive and therapeutic clinical strategies with particular aim on the various phases of Carcinogenesis. A published, peer-reviewed, clinical case report of Allotypic Immunomodulator therapy resulting in complete clinical remission of recurrent and metastatic Cancer is further discussed.

In summary, we propose that:

1. The sub-clinical progression of Carcinogenesis unto malignancy is significantly facilitated by a multi-factorial syndrome termed “Immunosenescence”;

2. Persistent reversal of Immunosenescence through the application of Allotypic Immunomodulator (AIM) strategies can facilitate elimination of pre-malignant and malignant targets at the cellular level, thereby limiting the progression of Carcinogenesis into its pathologic latter phases; and

3. The molecular mode of action of a prototypic, oligo-arabinoxylan AIM (fig. 1) may be one of an ‘oncosignal’ by virtue of its structural homology with the tetrasaccharide sialyl Lewis^x, a cell-surface carbohydrate determinant.

Figure 1 : RBAC, a prototype arabinoxylan
oligosaccharide AIM derived from Oryza sativa L.

<< Previous    [1]  2  3    Next >>